Science from Northern Scandinavia
WELCOME TO FINNADVANCE
MICROFLUIDICS AND MICROTECHNOLOGY SOLUTIONS
In the human body, cells make up different tissues, which have different mechanical properties. These mechanical cues in the local environment of the cells give rise to unique biochemical response either via extracellular matrix production or by cell signaling.
In routine cell biology studies, cells are grown on various different surfaces like polypropylene (PP), polystyrene (PS) and glass. It has been long known that the cell morphology observed in vitro is not reflected in these in vitro culture conditions.
With our microfluidic culture systems, and stiffness-matched ECM substrates, we aim to close the gap between in-vitro studies and in-vivo results.
Biomimetic microfluidic culture systems
Finnadvance has developed microfluidic devices for in-vitro microvascular network generation. We have developed a proof-of-concept device ready for vascular biology and drug testing studies, and showed mass-production capabilities with over 200 devices produced in 3 months. These devices can be fitted with wither a pump-based perfusion system, or a gravity-powered perfusion system on-chip.
We undertake custom chip design and fabrication projects for specific applications.
FinnAdvance’s microfluidic approach enables replicating precise biomechanical stimuli invitro, with precise control of flow velocities and 3D ECM stiffness.
We provide fully integrated microfluidics solutions, with no changes to your microscope/imaging systems
We are proud to have worked with projects in NASA Europa Challenge, TEKES Finland, OP bank Finland, and The Warren Alpert Medical School of Brown University to name a few.
NEWS & PROJECTS
Go Beyond the Known
We’ve been fortunate on many occasions to have our research published by the media in the press. If you’d like to stay up to date regarding our latest research projects, be entertained by stories about the research life, or get access to our informative resources, make sure you get in touch today.
Significant EU-funding for the research of vascular anomalies
July 05, 2018
FinnAdvance, together with their European partners have received nearly 3.8 million euro funding for the H2020-MSCA-ITN project called V.A. Cure. The goal is to provide doctoral education for early-stage researchers in the field of vascular biology, and uncover the disease causing mechanisms to establish novel therapeutic strategies for vascular anomalies.
Vascular anomalies are a diverse group of more than forty rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and even sudden death, and for which effective treatments are still lacking.
V.A. Cure assembles seven world-leading academic laboratories and five companies in Europe. The consortium will apply an intersectoral four-step approach: (1) the identification of novel genes involved in vascular anomalies in patients, (2) the dissection of molecular mechanisms behind the diseases by in vitro modelling, (3) the in-depth analysis of pathophysiological mechanisms through in vivo models, and (4) pre-clinical testing of identified treatment strategies.
FinnAdvance will develop a microfluidic vasculature-on-a-chip model for understanding of physical factors and flow effects in vascular anomalies and for pre-clinical testing. Microfluidic Organ-on-a-chip devices are readily being used to replace animal models, with a rapid setup and the ethics-free approach.
More information about the funder: Marie Skłodowska-Curie Innovative Training Networks
Image analysis for NASA challenge
April 12, 2025
Prateek Singh, from FinnAdvance, with partners from Turku have been selected in the NASA Europa challenge with their project DRONE-TREK- which analyses satellite and UAV images for algal bloom detection. Our project is among the top 20 and the final demo took place in Helsinki 29th – 31th of August 2017. Find the project here.
Finnadvance part of Finland’s efforts on nanobiotechnology derived therapeutics
February 29, 2020
Finnadvance has joined a new research consortium of Finnish pharmaceutical technology and academic research organisations to develop new organ-on-chip platforms for treatment and early diagnostics of central nervous system degenerative diseases and cancer. The consortium’s research will leverage blood-derived extracellular vesicles for potential drug delivery vehicles and biomarkers.
The consortium is formed of 13 partners, including Finland’s leading research organisations, the Finnish Red Cross Blood Service, Orion Pharma, University of Helsinki, University of Eastern Finland, Tampere University, VTT Oulu, UPM Biomedicals, the Biobank of Eastern Finland and innovative SMEs, Kaivogen, Timegate Instruments, Bionavis and Afekta.
The 3 year project (EVE – EV Ecosystem for Theranostic Platforms) is funded by Business Finland and headed by Dr. Saara Laitinen, R&D Manager at Finnish Red Cross Blood Service.
For more information on EVE, please contact:
Saara Laitinen, R&D Manager, Finnish Red Cross Blood Service, tel. +358 29 300 1695 saara.laitinen(at)veripalvelu.fi
FRCBS press release:
Don’t miss out on any lab news and updates.